Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance

Sigwart, 1988, Emergency stenting for acute occlusion after coronary balloon angioplasty, Circulation, 78, 1121, 10.1161/01.CIR.78.5.1121 Serruys, 1994, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease, N Engl J Med, 331, 489, 10.1056/NEJM199408253310801 Fischman, 1994, A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease, N Engl J Med, 331, 496, 10.1056/NEJM199408253310802 Bertrand, 2000, Circulation, 102, 624, 10.1161/01.CIR.102.6.624 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Ong, 2005, Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation, J Am Coll Cardiol, 45, 947, 10.1016/j.jacc.2004.09.079 Barragan, 2003, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation, Catheter Cardiovasc Interv, 59, 295, 10.1002/ccd.10497 Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 Cuisset, 2006, High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome, J Thromb Haemost, 4, 542, 10.1111/j.1538-7836.2005.01751.x Bonello, 2007, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events, J Thromb Haemost, 5, 1630, 10.1111/j.1538-7836.2007.02609.x Cuisset, 2006, Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non–ST-segment elevation acute coronary syndrome undergoing coronary stenting, J Am Coll Cardiol, 48, 1339, 10.1016/j.jacc.2006.06.049 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Aleil, 2005, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, 85, 10.1111/j.1538-7836.2004.01063.x Smith, 2006, J Am Coll Cardiol, 47, e1, 10.1016/j.jacc.2005.12.001 Bertrand, 2002, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 23, 1809, 10.1053/euhj.2002.3385 Schwarz, 1999, Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, 82, 1145, 10.1055/s-0037-1614344 Rao, 1988, Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase, J Am Coll Cardiol, 11, 1, 10.1016/0735-1097(88)90158-1 O’Riordan Blindt, 2007, The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis, Thromb Haemost, 98, 1329, 10.1160/TH07-05-0324 Schumacher, 2007, Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats, J Pharmacol Exp Ther, 322, 369, 10.1124/jpet.106.119156 Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting, J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030 Angiolillo, 2004, High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability, Eur Heart J, 25, 1903, 10.1016/j.ehj.2004.07.036 von Beckerath, 2005, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 Montalescot, 2006, J Am Coll Cardiol, 48, 931, 10.1016/j.jacc.2006.04.090 Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention, Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 Patti, 2005, Circulation, 111, 2099, 10.1161/01.CIR.0000161383.06692.D4 Gurbel, 2007, Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients, Thromb Res, 121, 107, 10.1016/j.thromres.2007.02.007 Soffer, 2003, Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?, Catheter Cardiovasc Interv, 59, 21, 10.1002/ccd.10494 Morel, 2007, Platelet responsiveness to clopidogrel in patients with coronary syndrome, Ann Cardiol Angeiol, 56, 21, 10.1016/j.ancard.2006.11.005 Campo, 2007, Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study, J Am Coll Cardiol, 50, 1132, 10.1016/j.jacc.2007.04.092